Drugs / Mesenchymal Precursor Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01290367 | Aug 2011 → Jul 2013 | lumbar disk degenerative disorder | Mesoblast, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-04-08 | Mesoblast, Inc. | Results Mesoblast R&D Day Presentation mesoblast.com ↗
Rexlemestrocel-L reduced myocardial infarctions (MIs), strokes and cardiovascular death. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-08 | Mesoblast, Inc. | Mesoblast R&D Day Presentation mesoblast.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mesenchymal Precursor Cells | “A Prospective, Double Blind, Controlled Study Evaluating Safety and Preliminary Efficacy of a Single Injection of Adult Mesenchymal Precursor Cells (MPCs) Combined With...” NCT01290367 ↗ |
| Known as | MPCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01290367 ↗ |
| Modality | Cell therapy | “immunoselected, culture-expanded, nucleated, allogeneic adult MPCs” NCT01290367 ↗ |
| Route | Other | “intradiscal injections” NCT01290367 ↗ |